<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064088</url>
  </required_header>
  <id_info>
    <org_study_id>UF9206</org_study_id>
    <nct_id>NCT02064088</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane Block in Pediatrics: Volume or Concentration ?</brief_title>
  <acronym>TAP Bloc</acronym>
  <official_title>Volume or Concentration for the Transverse Abdominal Plane Block in Children Aged 1-5 Years: Analgesic Effects and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The transversus abdominis plane (TAP) block provide a local anesthesia drug diffusion between
      the transverse abdominis muscle and the internal oblique muscle. TAP block reaches the
      anterior rami of spinal nerves from T7 to L1 involved in the innervation of homolateral
      abdominal wall. The transversus abdominis plane block has shown promise for perioperative
      analgesia, but data on the optimal dose regimen are limited.Following previous research of
      optimal dose of local anesthesic solution, the investigators aim to evaluate if a &quot;volume
      effect&quot; would lead to a better diffusion of the local anesthesic solution to the overall
      nervous roots. The local anesthesia drug choosen is levobupivacaine with a unique posology of
      0,4 mg/kg (either 0,2 ml/kg of 0,2% levobupivacaine for &quot;small volume&quot; group or 0,4 ml/kg of
      0,1% levobupivacaine for &quot;high volume&quot; group).With the same dose of levobupivacaine, this
      study aims to assess the impact of volume effect on analgesia efficiency as well as the
      security as after ultrasound TAP block on one to five years' old children who undergo a
      peritoneal-vaginal duct surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients for whom a rescue analgesia was necessary in post anesthesia care unit and ambulatory surgery unit</measure>
    <time_frame>from arrival in post anesthesia care unit until discharge (An expected average of 4 hours after end of surgery)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative opioid consumption : total Rémifentanil (µg/kg)</measure>
    <time_frame>for time of surgery (1 to 4 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative pain (FLACC scale) at hospital</measure>
    <time_frame>from recovery room until discharge (An expected average of 4 hours after end of surgery)</time_frame>
    <description>Post operative pain is evaluated every 15 minutes in the recovery room and then every two hours in the ambulatory surgical unit until discharge at home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatique peak of levobupivacaine (Cmax in µg/ml)</measure>
    <time_frame>5 min until 75 min after injection of local anaesthetic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time necessary to reach plasmatique peak of levobupivacaine (tmax in min)</measure>
    <time_frame>5 min until 75 min after injection of local anaesthetic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications related to local analgesia procedure</measure>
    <time_frame>until 24 hours in post operative</time_frame>
    <description>cardiovascular adverse event, adverse vascular ponction (positive aspiration test for blood), adverse peritoneal ponction, hematoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First request of rescue antalgic (Nubain or Tramadol)</measure>
    <time_frame>until 24 hours in post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consommation of rescue antalgic</measure>
    <time_frame>until 24 hours in post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain evaluation at home by parents (score PPMP)</measure>
    <time_frame>call between 24 and 48 hours in post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Inguinal or Ovarian Hernia</condition>
  <condition>Hydrocele</condition>
  <condition>Cord Kyst</condition>
  <condition>Local Analgesia Block</condition>
  <condition>One to Five Years</condition>
  <arm_group>
    <arm_group_label>Small volume</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local analgesia by one injection of 0,2 ml/kg of 0,2% lévobupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High volume</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local analgesia by one injection of 0,4 ml/kg of 0,1% lévobupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group</intervention_name>
    <description>Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles</description>
    <arm_group_label>Small volume</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group</intervention_name>
    <description>Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles</description>
    <arm_group_label>High volume</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalisation in ambulatory surgery and anesthesia unit for surgery of inguinal
             hernia or ovarian hernia or hydrocele or cord kyst

          -  Overall status: ASA I-II

          -  Aged from 1 to 5 years

          -  Informed consent

        Exclusion Criteria:

          -  Coagulation trouble

          -  Infection on ponction zone

          -  Local anesthesia drug or nonsteroidal anti inflammatory intolerance

          -  Cardiac/Renal/hepacticdysfunction

          -  Hemorrage, digestive perforation history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrystelle CS SOLA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Montpellier - Lapeyronie Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chrystelle CS SOLA, MD</last_name>
    <phone>+33 665849166</phone>
    <email>c-sola@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie SB BRINGUIER-BRANCHEREAU, PhD</last_name>
    <phone>+33 467338661</phone>
    <email>s-bringuierbranchereau@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrystelle CS SOLA, MD</last_name>
      <phone>+33 665849166</phone>
      <email>c-sola@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sophie SB BRINGUIER-BRANCHEREAU, PhD</last_name>
      <phone>+33 467338661</phone>
      <email>s-bringuierbranchereau@chu-montpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Chrystelle CS SOLA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe CD DADURE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier OR RAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain AR ROCHETTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>February 13, 2014</last_update_submitted>
  <last_update_submitted_qc>February 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Regional anesthesia</keyword>
  <keyword>TAP block</keyword>
  <keyword>Pediatric anesthesia</keyword>
  <keyword>analgesic effects</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

